Leishmaniasis in humans: drug or vaccine therapy?

M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …

A review of combination adjuvants for malaria vaccines: a promising approach for vaccine development

S Pirahmadi, S Zakeri, ND Djadid, AA Mehrizi - International journal for …, 2021 - Elsevier
It is obvious that there is a critical need for an efficient malaria vaccine to accelerate malaria
eradication. Currently, recombinant subunit vaccination against malaria using proteins and …

Recombinant PBP2a of methicillin-resistant S. aureus formulation in Alum and Montanide ISA266 adjuvants induced cellular and humoral immune responses with …

SS Mortazavi, S Haghighat, M Mahdavi - Microbial pathogenesis, 2020 - Elsevier
Staphylococcus aureus is an important cause of both hospital and community acquired
infections worldwide. S. aureus can develop multidrug resistance; thus, immunotherapy can …

Formulation of a recombinant HIV‐1 polytope candidate vaccine with naloxone/alum mixture: Induction of multi‐cytokine responses with a higher regulatory …

M Fathi, R Nezamzadeh, M Abdollahpour‐Alitappeh… - Apmis, 2021 - Wiley Online Library
The potency of a vaccine highly depends upon the nature of the adjuvant used. There are a
variety of ineffective vaccines, such as HIV‐1 vaccine candidates, that need to be optimized …

[HTML][HTML] Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine

M Yasaghi, M Mahdavi - Iranian journal of basic medical sciences, 2016 - ncbi.nlm.nih.gov
Objective (s): Many types of human papillomaviruses (HPVs) have been identified, with
some leading to cancer and others to skin lesions such as anogenital warts. Studies have …

Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation …

S Kalanaky, S Fakharzadeh, P Karimi, M Hafizi… - Viral …, 2023 - liebertpub.com
Despite the great success of vaccines in various infectious diseases, most current vaccines
are not effective enough, and on the contrary, clinically approved alum adjuvants cannot …

[HTML][HTML] Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses

M Haghighi, A Khorasani, P Karimi… - Iranian Journal of Basic …, 2022 - ncbi.nlm.nih.gov
Objective (s): SARS-CoV-2, emerging as a major threat to public health, has to be controlled
through vaccination. Naloxone (NLX), an opioid receptor antagonist, demonstrated its …

Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection

H Azizi, H Mirzaeei, AA Nasiri, A Bazi… - Experimental …, 2018 - Elsevier
Toxic effects of available therapeutics are major drawbacks for conventional management
approaches in parasitic infections. Vaccines have provided a promising opportunity to …

Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses

M Mirzaee, S Haghighat, B Golkaran… - Biomedical and …, 2022 - Elsevier
Objective This study aimed to investigate the effects of Montanide ISA-720 and Naloxone
(NLX) in Hepatitis B surface antigen (HBsAg) vaccine formulation on cytokine and long …

Formulation of FMD vaccine in Naloxone/Alum mixture: A potency study

D Alemalhoda, F Ajamian, A Khorasani, S Haghighat… - bioRxiv, 2022 - biorxiv.org
Abstract Background Current Foot-and-Mouth disease (FMD) vaccines are commonly
formulated in the alum adjuvant. Several studies showed that this form of vaccine, although …